<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800319</url>
  </required_header>
  <id_info>
    <org_study_id>ALK33-001</org_study_id>
    <nct_id>NCT00800319</nct_id>
  </id_info>
  <brief_title>ALK33-001: A Study of RDC-0313 Administered to Healthy Adults</brief_title>
  <official_title>ALK33-001: A Phase 1 Study of the Pharmacokinetics of RDC-0313 Administered to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of&#xD;
      RDC-0313 following oral administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, double-blind, ascending dose, placebo controlled study.&#xD;
      Dosing sequences will consist of 5 administrations of an oral solution of either ascending&#xD;
      doses of RDC-0313 or volume-match placebo. Dosing of cohorts will be staggered to allow a&#xD;
      blinded safety review to occur prior to dosing the next cohort. Subjects will be admitted to&#xD;
      the facility the morning before each dose, and will be required to fast overnight prior to&#xD;
      study drug administration. They will be discharged from the facility after the 36-hour&#xD;
      postdose assessments are completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentrations (Cmax) of RDC-0313</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant abnormal laboratory findings</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>RDC-0313, 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg of RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>volume-match placebo; single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDC-0313</intervention_name>
    <description>Oral solution given in 5, 15, 25, 50, and 75 mg single doses</description>
    <arm_group_label>RDC-0313, 15 mg</arm_group_label>
    <arm_group_label>RDC-0313, 25mg</arm_group_label>
    <arm_group_label>RDC-0313, 50 mg</arm_group_label>
    <arm_group_label>RDC-0313, 5mg</arm_group_label>
    <arm_group_label>RDC-0313, 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Volume matched placebo; oral solution; single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 65 years of age&#xD;
&#xD;
          -  Body mass index of 19-30 kg/m2 at screening&#xD;
&#xD;
          -  If subject is female and of childbearing potential, she must agree to use an&#xD;
             acceptable method of contraception&#xD;
&#xD;
          -  If subject is male, he must agree to reduce the risk of a female partner becoming&#xD;
             pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and/or currently breastfeeding&#xD;
&#xD;
          -  Clinically significant medical condition or observed abnormalities&#xD;
&#xD;
          -  Clinically significant illness within 30 days of the first study drug administration&#xD;
&#xD;
          -  History of opioid dependence&#xD;
&#xD;
          -  Positive urine toxicological screen for marijuana, cocaine, amphetamines, opioids,&#xD;
             barbiturates, and benzodiazepines&#xD;
&#xD;
          -  Positive resolut for any serology test performed at screening&#xD;
&#xD;
          -  Use of alcohol-, caffeine-, or xanthine-containing products&#xD;
&#xD;
          -  Tobacco use within 90 days before the first study drug administration&#xD;
&#xD;
          -  Participation in a clinical trial within 30 days before screening&#xD;
&#xD;
          -  Requirement of a special diet other than vegetarian, or significant food allergy or&#xD;
             intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T. Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase One Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Phase One Services</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol dependence</keyword>
  <keyword>Opioid antagonist</keyword>
  <keyword>RDC-0313</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ALKS-33</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

